

# Grŵp Strategaeth Meddyginiaethau Cymru Gyfan All Wales Medicines Strategy Group



## Final Appraisal Recommendation

Advice No: 1418 – September 2018

**Lanreotide (Somatuline® Autogel®) 120 mg solution for injection in a prefilled syringe**

**Limited submission by Ipsen Ltd**

### Recommendation of the All Wales Medicines Strategy Group

**Lanreotide (Somatuline® Autogel®) is recommended as an option for use within NHS Wales for the treatment of grade 1 and a subset of grade 2 (Ki67 index up to 10%) gastroenteropancreatic neuroendocrine tumours (GEP-NETs) of midgut, pancreatic or unknown origin where hindgut sites of origin have been excluded, in adult patients with unresectable locally advanced or metastatic disease.**

#### Additional note(s):

- AWMSG considered that lanreotide (Somatuline® Autogel®) satisfied the AWMSG criteria for a medicine developed specifically for rare diseases.
- AWMSG were of the view that prescribing should be initiated by a specialist clinician within secondary care.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 1988), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

The All Wales Therapeutics and Toxicology Centre (AWTTC) reviewed this appraisal recommendation in April 2022. No new evidence was identified that is likely to significantly affect the current recommendation. Therefore, this recommendation has been transferred to AWMSG's static list of medicine recommendations.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation – 1418: Lanreotide (Somatuline® Autogel®) 120 mg solution for injection in a prefilled syringe. September 2018.